Please assess the completion status of the following clinical trial:

Trial Title: Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 - 75, male or non-pregnant female;~2. Stable or unstable angina with evidence of myocardial ischemia, or patient with myocardial infarction;~3. Coronary angiography reveals stenosis lesions;~4. Discovery of ADP induced platelet inhibition rate \< 50% and MAADP \>47mm via thromboelastography (indicating low responsiveness to Clopidogrel with high risk for stent thrombosis formation);~5. Is able to understand the objective of the trial, takes part voluntarily and signs the written informed consent form.~Exclusion Criteria:~1. Those who have participated in other drug or therapy equipment clinical trials but did not reach the main study endpoint time limit;~2. Symptoms of severe heart failure (NYHA Class III and above) or left ventricular ejection fraction \< 40% (ultrasound or left ventricle ngiography);~3. Pregnant or lactating women;~4. severely impaired renal function before surgery: serum creatinine \> 2.0mg/dl;~5. Impaired liver function before surgery: Serum GPT \> 120U/L;~6. Bleeding tendency, history of active peptic ulcer, history of cerebral hemorrhage or cavum subarachnoidale bleeding, patients with antiplatelet agent and anticoagulant treatment contraindications and hence are unable to undergo anticoagulant therapy;~7. Patients who are unable to withstand dual antiplatelet therapy due to allergy to Aspirin, Clopidogrel or ticlopidine, heparin, contrast agent, paclitaxel and metals;~8. Leucocyte \< 3.5 x 109; and/or platelet \< 100,000/mm3 or \> 750,000/mm3;~9. Patient's life expectancy is less than 12 months;~10. Patients who plan to undergo coronary artery bypass grafting or other surgery within 1 year;~11. Those waiting for heart transplant;~12. Patients who are deemed by the researchers to have low compliance and unable to abide by the requirements and complete the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel + Aspirit (Type: ACTIVE_COMPARATOR): A Standard antiplatelet therapy control group： Clopidogrel 75mg Qd + Aspirin 100mg Qd
- Clopidogrel + Aspirin (Type: ACTIVE_COMPARATOR): B Double-dosage Clopidogrel group： Clopidogrel 150mg Qd + Aspirin 100mg Qd
- Clopidogrel + Aspirin + Cilostazol (Type: ACTIVE_COMPARATOR): C triple antiplatelet therapy group： Cilostazol 100mg Bid + Aspirin 100mg Qd + Clopidogrel 75mg Qd

Based on this trial design, predict the completion outcome and termination type (if applicable).